116 related articles for article (PubMed ID: 35076073)
1. The protein level of the tumour-promoting factor SET is regulated by cell density.
Kohyanagi N; Kitamura N; Tanaka K; Mizuno T; Fujiwara N; Ohama T; Sato K
J Biochem; 2022 Mar; 171(3):295-303. PubMed ID: 35076073
[TBL] [Abstract][Full Text] [Related]
2. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ
Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Torrejón B; Cristóbal I; Caramés C; Prieto-Potín I; Chamizo C; Santos A; Sanz-Alvarez M; Serna-Blasco R; Luque M; Madoz-Gúrpide J; Rojo F; García-Foncillas J
World J Surg; 2018 Nov; 42(11):3771-3778. PubMed ID: 29796729
[TBL] [Abstract][Full Text] [Related]
5. Ceramide in the prostate.
Dent P
Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
[TBL] [Abstract][Full Text] [Related]
6. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
7. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
8. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.
Arnaud L; Chen S; Liu F; Li B; Khatoon S; Grundke-Iqbal I; Iqbal K
FEBS Lett; 2011 Sep; 585(17):2653-9. PubMed ID: 21806989
[TBL] [Abstract][Full Text] [Related]
10. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.
Mukhopadhyay A; Saddoughi SA; Song P; Sultan I; Ponnusamy S; Senkal CE; Snook CF; Arnold HK; Sears RC; Hannun YA; Ogretmen B
FASEB J; 2009 Mar; 23(3):751-63. PubMed ID: 19028839
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
12. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
[TBL] [Abstract][Full Text] [Related]
13. Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).
Jiang SW; Xu S; Chen H; Liu X; Tang Z; Cui Y; Liu J
Clin Chim Acta; 2017 Jan; 464():155-159. PubMed ID: 27836688
[TBL] [Abstract][Full Text] [Related]
14. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.
Shu G; Zhang L; Jiang S; Cheng Z; Wang G; Huang X; Yang X
Oncotarget; 2016 Jun; 7(26):40285-40296. PubMed ID: 27244888
[TBL] [Abstract][Full Text] [Related]
15. SET levels contribute to cohesion fatigue.
Yang L; Zhang Q; Niu T; Liu H
Mol Biol Cell; 2021 Jun; 32(13):1256-1266. PubMed ID: 33909454
[TBL] [Abstract][Full Text] [Related]
16. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
18. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
19. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
